Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Daily news and press releases about Healthcare

older | 1 | .... | 1105 | 1106 | (Page 1107) | 1108 | 1109 | .... | 1118 | newer

    0 0

     



    (EMAILWIRE.COM, December 04, 2018 ) Rainwater Harvesting Market Global Analysis:
    It analyses the past and current Rainwater Harvesting market values along with spotless study of the Rainwater Harvesting market in order to predict future market condition, trends, risk, challenges and opportunities between the forecast periods from 2018 to 2023. The information will help shareholders and other business people to have a predominant understandings of the importance in which the Rainwater Harvesting global Rainwater Harvesting market is handled.

    Further the Rainwater Harvesting Industry research report focuses on competitive landscape and leading top market players governing the whole industry with facts and details such as sales, contact details, product specifications & pictures and market share.

    Market Segmented by Prominent Players are:
    Rainwater Management Solutions, Caldwell Tanks, Norwesco, Snyder, BUSHMAN, Pioneer Water Tanks, Lakota Water Companym, BRAE, Wahaso, CST Industries , ROTH North America, Innovative Water Solutions, Mountain & Mesa Construction BH Tank, The RainCatcher

    Ask for the Sample Report: https://www.reportsweb.com/inquiry&RW00012283942/sample

    Objective:

    This research survey shares evolving new developments and technological trends through which our customers will be able shape their deep rooted innovative developments, set informative businesses options and also to perform important essentials.

    The restraints, demand drivers, Rainwater Harvesting manufacturing technology and technological foundations are identified after a deep research on the Rainwater Harvesting market’s efficiency. Further, it explains supply chain, financial support, retailer’s analysis and marketing channels. The Rainwater Harvesting Industry study report look into the sales volume of Rainwater Harvesting along with revenue, production, sales, supply and consumption, market share and growth rate of each type and application alongside top to bottom research. A few different factors, for example, import, export, gross margin, value and cost are likewise examined.

    Market Segmented by Types are :
    Tanks, Accessories, Service

    Market Segmented by Applications are:
    Commercial Segment, Residential Segment, Industrial Segment

    Rainwater Harvesting Market Research Highlights:

    Revenue Forecast
    Year on Year Growth
    Emerging Regions
    Top Companies
    Go For Interesting Discount Here: https://www.reportsweb.com/inquiry&RW00012283942/discount

    Our teams of analysts have successfully marked contemplated policy changes, favourable circumstances, industry news, developments and trends. Organization can mobilize all of this data to reinforce their market presence it packs different components of data collected from secondary sources including magazines, Internet, journals and press releases in the form of graphs, tables, number and pie-charts. The information is verified and validated through primary interviews and questionnaire.

    Benefits of Buying this Rainwater Harvesting Market Research Report:

    -Analyst backing: Get correct answers of your queries from our analyst’s team of experts before and after purchasing the report.
    -Meet Customer’s Requirements: Our expert team will assist with all your research requirements and customize the report.
    -Unique Expertise: Experts will give brilliant insights about the report.
    -Assured Quality: We focus on the quality and accuracy of the report.

    Moreover, it describes the market segment upstream and downstream, Raw Material and Suppliers, then analysis of global Rainwater Harvesting market cost structure, technical data and manufacturing plants capacity and commercial production. Evaluation of the market size and forecast of Rainwater Harvesting by product, region and application between the years 2018 to 2023 are also mentioned.


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.

    Don’t miss out on business opportunities in “Autoinjectors Market”. Speak to our analyst and gain crucial industry insights that will help your business grow: http://bit.ly/2Q7wlrE
    Autoinjectors offer several advantages, such as reduces the chances of needlestick injuries, reduce needle phobia anxiety, maintain consistency regarding dose accuracy, and aid in better efficacy, which, in turn, help in the growth of the market. The autoinjectors market is expanding with the technological advancement and new design development. These autoinjectors are being used in many therapies such as rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies.
    Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors market
    Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia. Thus, the demand for autoinjectors for this therapy segment is fueled by the increasing incidence of RA across the globe. Among the various treatment options available for RA in the market, autoinjectors are the most advanced and convenient mode of tretment currently avialble in the market.

    Browse and in-depth TOC on “Autoinjectors Market”
    66 - Tables

    36 - Figures

    133 - Pages

    View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html

    North America to dominate the market in 2018

    The autoinjectors market comprises a network of players involved in the research and product development; component manufacturing; distribution and sale; and post-sales services. Key players considered in the analysis of the autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players are Merck (US), SHL Group (Taiwan), Ypsomed (Switzerland), AstraZeneca (UK), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), J&J (US), and Haselmeier (Switzerland).

    Major Market Developments
    In April, 2018, Abbvie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe.
    In August, 2017, Amgen and Humana entered in to collaborative agreement for the development and research of medicines for multiple serious conditions including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer.
    In May, 2018, Received EU approval for Repatha autoinjector. Similarly, the company has launched Enbrel auto-touch auto-injector in November, 2017.
    Request for Free Sample Report @ http://bit.ly/2DXG2BC
    Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting
    About MarketsandMarkets™

    MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

    Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

    MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

    Contact:

    Mr. Shelly Singh
    MarketsandMarkets™ INC.
    630 Dundee Road
    Suite 430
    Northbrook, IL 60062
    USA: 1-888-600-6441
    Email: sales@marketsandmarkets.com
    Research Insight: https://www.marketsandmarkets.com/ResearchInsight/autoinjector-market.asp
    Visit Our Website: https://www.marketsandmarkets.com


    Mr. Shelly Singh
    1-888-600-6441
    sales@marketsandmarkets.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) According to the new market research report “Track etched Membrane Market by Product (Membrane Filter, Capsule & Cartridge Filter, Cell Culture Insert), Material (Polycarbonate, Polyimide), Application (Cell Biology, Microbiology, Analytical testing, Automotive), End User - Global Forecast to 2023", published by MarketsandMarkets™, The track etched membrane market is expected to reach USD 813.1 million by 2023 from USD 476.0 million in 2018, at a CAGR of 11.3% from 2018 to 2023. The growth of the pharmaceutical R&D expenditure is expected to be one of the major factors driving the growth of this market during the forecast period. Moreover, the collaborative application of nanotechnology and track etching is expected to increase the adoption of track etched membranes in various applications, such as healthcare, fuel cells, telecommunications, and transportation.

    Don’t miss out on business opportunities in Track etched Membrane Market. Speak to our analyst and gain crucial industry insights that will help your business grow: http://bit.ly/2DYs5TV
    Early buyers will receive 10% customization on reports.

    The track etched membrane market is expected to reach USD 813.1 million by 2023 from USD 476.0 million in 2018, at a CAGR of 11.3% from 2018 to 2023. Key factors driving the growth of this market include increasing R&D spending in the pharmaceutical and biopharmaceutical industries and increasing purity requirements among end users of track etched membranes. However, the high cost of production and the limited supply of track etched membranes are major factors that are expected to restrain the growth of this market during the forecast period.

    The report analyzes the global track etched membrane market, by product, material, application, end user, and region. By product, the membrane filters segment is expected to lead the track etched membrane market by 2023. The large share of this segment can be attributed to the increasing applicability of membrane filters in sterilizing, final filtration, sample preparation, filtration of aqueous and organic solutions, fluid monitoring, and venting and gas filtration.

    Geographically, the global track etched membrane market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to continue to dominate the track etched membrane market till 2023, followed by Europe and Asia Pacific. The large share of the North American market can be attributed to the presence of global pharmaceutical manufacturers, a large number of quality control laboratories for the food & beverage industry, and growing concern towards improving the quality of food products and the medical devices that utilize track etched membranes.

    Browse and in-depth TOC on “Track etched Membrane Market”
    85 - Tables

    37 - Figures

    140 - Pages

    View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/track-etched-membrane-market-42556211.html

    Key players in the global track etched membrane are GE Healthcare (US), Danaher (US), Corning (US), Merck (Germany), it4ip (Belgium), Sterlitech (US), Oxyphen (Switzerland), Sarstedt (US), BRAND GMBH (Germany), Sartorius (Germany), SABEU (Germany), Zefon Internat ional (US), GVS (Italy), Thermo Fisher Scientific (US), Eaton (Ireland), Greiner Bio-One (Austria), MACHEREY-NAGEL (Germany), Avanti Lipids Polar (US), SKC (US), Advantec (Canada), Avestin (Canada), CHMLAB (Spain), Scaffdex (Finland), and Graver Technologies (US).

    Request for Free Sample Report @ http://bit.ly/2KPuBxe

    Browse Adjacent Markets @ Biotechnology Market Research Reports & Consulting

    About MarketsandMarkets™

    MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

    Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

    MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

    Contact:

    Mr. Shelly Singh
    MarketsandMarkets™ INC.
    630 Dundee Road
    Suite 430
    Northbrook, IL 60062
    USA: 1-888-600-6441
    Email: sales@marketsandmarkets.com
    Research Insight: https://www.marketsandmarkets.com/ResearchInsight/track-etched-membrane-market.asp
    Visit Our Website: https://www.marketsandmarkets.com


    Mr. Shelly Singh
    1-888-600-6441
    sales@marketsandmarkets.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) It further provides Entyvio`s patents (US & EU). It also features the historical and forecasted sales of Entyvio till 2022. The report also throws light on Entyvio`s market competition and emerging therapies in the same space as Entyvio. A SWOT analysis of Entyvio is also featured.
    -Depending on information availability

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283168/sample

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.



    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283168/discount

    Scope of the report
    -A comprehensive product overview including product description, regulatory milestones, clinical trials, deals and partnerships, have been elaborated in this report
    -Patent information around Entyvio in United States (US) and Europe (EU) has been highlighted
    -The report contains historical and forecasted sales for Entyvio till 2022
    -Comprehensive coverage of the emerging therapies (Phase III) in the space where Entyvio operates including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical information
    -The report also features the SWOT analysis of Entyvio



    Reasons to Buy
    -Establish a comprehensive understanding of the drug, Entyvio
    -Plan developmental timelines around Entyvio`s patents for the major markets-US and EU
    -Understand Entyvio`s current and future growth through its historical and forecasted sales
    -Identify and understand the current in-market competitors for Entyvio
    -Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
    -Identify and plan ahead for prospective emerging players and their products operating in the same space as Entyvio
    -Identify opportunities in the same area as Entyvio with Publisher`s SWOT analysis

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283168/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 10+ products along with 10+ companies involved.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283169/sample



    Top Key Players: –
    Adare Pharmaceuticals
    Atopix Therapeutics
    Biotica Pharmaceuticals
    Calypso Biotech
    Celgene
    DBV Technologies
    GlaxoSmithKline
    Novartis
    Quorum Innovations
    Sanofi/Regeneron
    Shire
    Teva



    Products covered by Phase
    -Phase III and Phase II
    -Pre-clinical
    -Inactive (Dormant and Discontinued)

    Overview of pipeline development activities for Eosinophilic Esophagitis
    Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

    Therapeutic segmentation of products for Eosinophilic Esophagitis
    The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.



    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283169/discount

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    -Provides an overview of therapeutic pipeline activity for Eosinophilic Esophagitis across the complete product development cycle including all clinical and non-clinical stages
    -It comprises of detailed profiles of Eosinophilic Esophagitis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
    -Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    -Coverage of dormant and discontinued pipeline projects across Eosinophilic Esophagitis



    Reasons to Buy
    -Establish a comprehensive understanding of the current pipeline scenario across Eosinophilic Esophagitis to formulate effective R&D strategies
    -Assess challenges and opportunities that influence Eosinophilic Esophagitis R&D
    -Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    -Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
    -Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Eosinophilic Esophagitis to enhance and expand business potential and scope
    -Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283169/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 20+ products along with 15+ companies involved.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283171/sample



    Top Key Players: –
    Arena Pharmaceuticals
    Avadel Pharmaceuticals
    Balance Therapeutics
    Evotec AG
    GlaxoSmithKline
    Heptares Therapeutics
    Jazz Pharmaceuticals
    Johnson & Johnson
    NLS Pharma
    Ono Pharmaceutical
    OptiNose
    Pfizer
    Reset Therapeutics
    Roche
    Sanofi
    Seelos Therapeutics
    Taisho Pharmaceutical
    Takeda
    Theranexus



    Products covered by Phase
    -Phase III, Phase II, Phase I and IND
    -Pre-clinical & Discovery
    -Inactive (Dormant and Discontinued)

    Overview of pipeline development activities for Narcolepsy
    Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283171/discount



    Therapeutic segmentation of products for Narcolepsy
    The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    -Provides an overview of therapeutic pipeline activity for Narcolepsy across the complete product development cycle including all clinical and non-clinical stages
    -It comprises of detailed profiles of Narcolepsy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
    -Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    -Coverage of dormant and discontinued pipeline projects across Narcolepsy



    Get More Information : https://www.reportsweb.com/inquiry&RW00012283171/buying

    Reasons to Buy
    -Establish a comprehensive understanding of the current pipeline scenario across Narcolepsy to formulate effective R&D strategies
    -Assess challenges and opportunities that influence Narcolepsy R&D
    -Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    -Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
    -Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Narcolepsy to enhance and expand business potential and scope
    -Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) The report provides the detailed analysis of 30+ products along with 20+ companies involved. The report also covers a separate section for the Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers. European Commission has granted Orphan Drug Designation to IPH4102 for the treatment of Cutaneous T-Cell Lymphoma.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283172/sample



    Top Key Players: –
    Affimed
    Altor Bioscience Corporation
    AvidBiotic Corporation
    Bristol-Myers Squibb
    Celgene
    CureTech
    CytoVac
    Dynavax
    Fate Therapeutics
    Five Prime Therapeutics
    Fortress Biotech



    Products covered by Phase
    -Phase II and Phase I
    -Pre-clinical

    Overview of pipeline development activities for Natural Killer Cell Therapies
    Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

    Therapeutic segmentation of products for Natural Killer Cell Therapies
    The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Cell Therapy.



    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283172/discount

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope
    -The report provides competitive pipeline landscape of Natural Killer Cell Therapies
    -The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    -The report provides the insight of current and future market for Natural Killer Cell Therapies
    -The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    -Coverage of the Natural Killer Cell Therapies pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    -The report reviews key players involved in the therapeutics development for Natural Killer Cell Therapies and also provide company profiling
    -Pipeline products coverage based on various stages of development ranging from mid stage till preclinical stages
    -Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type



    Get More Information : https://www.reportsweb.com/inquiry&RW00012283172/buying

    Reasons to Buy
    -Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    -Establish a comprehensive understanding of the current pipeline scenario across Natural Killer Cell Therapies to formulate effective R&D strategies
    -Assess challenges and opportunities that influence Natural Killer Cell Therapies R&D
    -Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    -Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
    -Devise corrective measures for pipeline projects by understanding Natural Killer Cell Therapies pipeline depth and focus of Indication therapeutics
    -Developing strategic initiatives to support your drug development activities
    -Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Natural Killer Cell Therapies to enhance and expand business potential and scope
    -Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
    -Gaining a full picture of the Competitive Landscape for Evidence based Decisions


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 30+ products along with 20+ companies involved.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283173/sample



    Top Key Players: –
    Adolor Corporation
    Alkermes
    Astraea Therapeutics
    BlackThorn Therapeutics
    Camurus
    Eli Lilly
    Elorac
    GlaxoSmithKline
    INSYS Therapeutics
    Janssen Pharmaceuticals
    Japan Tobacco



    Products covered by Phase
    -Phase III, Phase II and Phase I
    -Pre-clinical and Discovery
    -Inactive (Dormant and Discontinued)

    Overview of pipeline development activities for Opioid Receptor Antagonists
    Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283173/discount



    Therapeutic segmentation of products for Opioid Receptor Antagonists
    The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    -Provides an overview of therapeutic pipeline activity for Opioid Receptor Antagonists across the complete product development cycle including all clinical and non-clinical stages
    -It comprises of detailed profiles of Opioid Receptor Antagonists therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
    -Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    -Coverage of dormant and discontinued pipeline projects across Opioid Receptor Antagonists

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283173/buying

    Reasons to Buy
    -Establish a comprehensive understanding of the current pipeline scenario across Opioid Receptor Antagonists to formulate effective R&D strategies
    -Assess challenges and opportunities that influence Opioid Receptor Antagonists R&D
    -Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    -Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
    -Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Opioid Receptor Antagonists to enhance and expand business potential and scope
    -Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 15+ products along with 15+ companies involved.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW00012283174/sample



    Top Key Players: –
    UCB
    Acerta Pharma
    Exelixix
    GlaxoSmithKline
    Hutchison MediPharma
    Incyte
    Incyte Corporation
    Johnson & Johnson
    MEI Pharma
    Merck
    Novartis
    Rhizen Pharmaceuticals



    Products covered by Phase
    -Phase III, Phase II and Phase I
    -Pre-clinical and Unknown
    -Inactive (Dormant)

    Overview of pipeline development activities for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors
    Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

    Therapeutic segmentation of products for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors
    The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.



    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283174/discount

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    -Provides an overview of therapeutic pipeline activity for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors across the complete product development cycle including all clinical and non-clinical stages
    -It comprises of detailed profiles of Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
    -Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    -Coverage of dormant pipeline projects across Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283174/buying

    Reasons to Buy
    -Establish a comprehensive understanding of the current pipeline scenario across Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors to formulate effective R&D strategies
    -Assess challenges and opportunities that influence Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors R&D
    -Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
    -Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
    -Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors to enhance and expand business potential and scope
    -Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 35+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. Publisher's Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 25+ active companies involved in the therapeutic development of the products.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001608701/sample

    Top Key Players: -
    Aptose Biosciences
    Astellas Pharma
    Theravance Biopharma
    Theravance Biopharma
    Vectura Group plc
    Japan Tobacco Company
    Hoffmann-La Roche
    Astrazeneca
    AbbVie
    Galapagos NV
    Incyte Corporation
    Pfizer

    Report Scope

    -The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors
    -The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    -The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors
    -The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    -Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    -The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling
    -The report also gives the information of dormant pipeline projects
    -Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    -Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001608701/discount ;

    Reasons to Buy

    -Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    -Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors
    -Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    -Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics
    -Developing strategic initiatives to support your drug development activities.
    -Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    -Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    -Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    -Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    -Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Get More Information : https://www.reportsweb.com/inquiry&RW0001608701/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Immune Checkpoints Activators. This report provides information on the therapeutic development based on Immune Checkpoints Activators mechanism of action dealing with around 40+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. Publisher's Report also assesses the Immune Checkpoints Activators therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001608702/sample

    Top Key Players: -
    Aduro Biotech
    Agenus
    Apexigen
    Apogenix GmbH
    BioInvent
    Bristol-Myers Squibb
    Celldex Therapeutics
    Checkpoint Therapeutics, Inc.
    Enumeral
    Eutilex Co. Ltd.


    Report Scope

    -The report provides competitive pipeline landscape of Immune Checkpoints Activators
    -The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    -The report provides the insight of current and future market for Immune Checkpoints Activators
    -The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    -Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    -The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
    -The report also gives the information of dormant pipeline projects
    -Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    -Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW0001608702/discount


    Reasons to Buy

    -Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    -Complete MOA intelligence and complete understanding over therapeutics development for Immune Checkpoints Activators
    -Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    -Devise corrective measures for pipeline projects by understanding Immune Checkpoints Activators pipeline depth and focus of Indication therapeutics
    -Developing strategic initiatives to support your drug development activities.
    -Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    -Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    -Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    -Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    -Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Get More Information : https://www.reportsweb.com/inquiry&RW0001608702/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 120+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. Publisher's Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 28+ active companies involved in the therapeutic development of the products.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001608703/sample

    Top Key Players: -
    Arbele Limited
    Apceth
    Aurora Biopharma
    Autolus Limited
    Avacta Life Sciences Limited
    Beijing Biohealthcare Biotechnology Co.,Ltd
    Beijing Doing Biomedical Co., Ltd.
    Beijing Sanwater Biological Technology Co., Ltd.
    Bellicum Pharmaceuticals Inc.
    Benitec Biopharma Limited

    Report Scope

    -The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
    -The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    -The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
    -The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    -Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    -The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
    -The report also gives the information of dormant pipeline projects
    -Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    -Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW0001608703/discount ;

    Reasons to Buy

    -Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    -Complete MOA intelligence and complete understanding over therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
    -Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    -Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
    -Developing strategic initiatives to support your drug development activities.
    -Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    -Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    -Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    -Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    -Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Get More Information : https://www.reportsweb.com/inquiry&RW0001608703/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on the Natural Killer Cell based therapies profiles along with the augmenting therapies covering their pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens. The report provides the NK Cell based therapies licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis.



    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001761673/sample

    Reports Highlights:
    NK cell Therapy Pipeline scenario which includes NK cell therapies and NK cell augmenting therapies.
    Collaborations & partnering deals
    Current Prominent Research Areas and Key Players
    Pipeline product profiles NK Cell therapy Technologies and NK cell Augmenting Therapies
    Licensing opportunities
    Market Drivers and Barriers

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW0001761673/discount

    Scope
    Overview of the global NK cell therapy and NK cell augmenting therapies pipeline scenario, products and associated companies information
    Coverage of global NK cell therapies and drugs that enhance the activity of NK under development
    Competitive landscape of products for key players and related indications
    Coverage of licensors, collaborators and development partners, deal terms and deal values estimation
    Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
    Highlights of licensing & collaboration opportunities and funding details
    Highlights of latest NK cell therapy technologies and NK cell augmenting therapies and innovative companies
    Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis

    Get More Information : https://www.reportsweb.com/inquiry&RW0001761673/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Microbiome. This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company's information involved in the therapeutic development of the products.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher team of industry experts.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001761674/sample

    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

    Reports Highlights:
    Microbiome Pipeline scenario
    Collaborations & partnering deals
    Current Prominent Research Areas and Key Players
    Pipeline product profiles Microbiome Technologies
    Licensing opportunities
    Market Drivers and Barriers

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW0001761674/discount

    Scope
    Overview of the global Microbiome pipeline scenario, products and associated companies information
    Coverage of global Microbiome therapies under development
    Competitive landscape of products for key players and related indications
    Coverage of licensors, collaborators and development partners, deal terms and deal values estimation
    Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
    Highlights of licensing & collaboration opportunities and funding details
    Highlights of latest Microbiome technologies
    Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis

    Get More Information : https://www.reportsweb.com/inquiry&RW0001761674/buying

    Reasons to Buy
    Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    Complete MOA intelligence and complete understanding over therapeutics development for Microbiome therapies
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    Devise corrective measures for pipeline projects by understanding Microbiome pipeline depth and focus of Indication therapeutics
    Developing strategic initiatives to support your drug development activities.
    Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) Publisher's "Chemotherapy Induced Nausea and Vomiting (CINV)- Epidemiology Insights-2023" Report provides an overview of the disease, historical and forecasted epidemiological data for the Incident cases of Chemotherapy Induced Nausea and Vomiting (CINV) from 2013-2023 for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001713514/sample

    Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can't get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn't be physically string to bear the chemotherapy side-effects.

    According to Publisher, the Incident cases Chemotherapy Induced Nausea and Vomiting (CINV) is increasing and is expected to be 2, 79,634 by 2023.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW0001713514/discount

    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Scope
    The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.
    Insightful review of the key market drivers and barriers.
    To understand the regulatory scenario in major markets.
    The Report covers the detailed historical and forecasted Chemotherapy Induced Nausea and Vomiting (CINV) epidemiology cases covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

    Get More Information : https://www.reportsweb.com/inquiry&RW0001713514/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk factors, disease burden with special emphasis.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001713515/sample

    Acromegaly is a rare but serious hormonal disorder caused by excessive growth hormone (GH) in the blood in adults. Acromegaly in adults occurs mainly in middle-aged men and women. In This condition, the bones increase in size, including those of the hands, feet and face. Acromegaly is uncommon and physical changes occur gradually thus the condition often isn't recognized immediately and if not treated promptly, it can lead to serious illness and even become life-threatening. According to Publisher's estimates, the prevalent cases of Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.
    Gigantism is excessive production of GH in children which is extremely rare and leads to exaggerated bone growth and an abnormal increase in height. It results from high linear growth due to excessive action of insulin like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood. According to Publisher's estimates, prevalent cases of Gigantism in the 6 MM are expected to increase with a CAGR of 2% and Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW0001713515/discount

    Key Coverage and Benefits:

    The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Acromegaly and Gigantism.
    Identifying prevalent patient populations as well as risk factors in the global Acromegaly and Gigantism market will help to improve product design, pricing, and launch plans.

    Get More Information : https://www.reportsweb.com/inquiry&RW0001713515/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) This is considered as multiple bladder condition as it can lead to many other problems. Current studies estimate that 2.7% to 6.5% of women in the United States have symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS). PBS/IC is more common in women, with a female/male ratio that ranges from 5:1 to 10:1 and the Median age at diagnosis is 42 to 46 yr old whereas men are diagnosed at a younger age. According to Publisher, the number of Incident Probable IC cases in 7 major markets is expected to reach 1,97,086 cases in 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001713516/sample


    Scope

    The report will help in developing business strategies by understanding the trends shaping and driving the global interstitial cystitis scenario.
    Review of the key market drivers and barriers.
    To understand the regulatory scenario in major markets.
    The Report covers the detailed global historical and forecasted Interstitial Cystitis Epidemiology covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) It includes 10 years epidemiology historical and forecasted data of Urinary Incontinence prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Urinary Incontinence . The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001540159/sample


    Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

    Scope of the Report
    - The Report includes the prevalent population and how will it change over the next eight years.
    - Prevalent or incident cases segmented by age and sex.
    - Coverage of key Urinary Incontinence subpopulations and its prevalent or incident cases
    - The key differences in epidemiology patterns across the seven market segments

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW0001540159/discount

    Key Coverage and Benefits
    - The report will help in developing business strategies by understanding the trends shaping and driving the global Urinary Incontinence market.
    - Identifying prevalent patient populations as well as risk factors in the global Urinary Incontinence market will help to improve product design, pricing, and launch plans.
    - Organize sales and marketing efforts by identifying the best opportunities for Urinary Incontinence therapeutics in each of the markets covered.


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 05, 2018 ) It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023.
    Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.
    According to Publisher, the prevalent cases of Sarcopenia in 7 MM are expected to increase and reach up to 42,969,489 cases by the end of year 2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Get a Sample Report: https://www.reportsweb.com/inquiry&RW0001713517/sample

    Key Coverage and Benefits:

    The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Sarcopenia.
    Identifying prevalent patient populations as well as risk factors of Sarcopenia.


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, December 06, 2018 ) According to the new market research report “Wireless Health Market by Technology (WPAN, WLAN/Wifi, WiMAX), by Component (Hardware, Software, & Services), by Application (Patient Specific and Provider/Payer Specific), & by End Users (Providers, & Payers) - Analysis & Global Forecast to 2020", published by MarketsandMarkets™, This report studies the global wireless health market for the forecast period of 2015 to 2020. This market is expected to reach USD 110.12 Billion by 2020 from USD 39.03 Billion in 2015, at a CAGR of 23.1%.

    View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/wireless-healthcare-market-551.html

    The report segments the market of wireless health based on technologies, components, applications, end users, and regions. On the basis of technologies, the market is further segmented into WPAN, WLAN/WiFi, WiMAX, and WWAN. The WPAN technology market segment accounts for the largest share of the global market in 2015. The WPAN technology segment is further segmented into Bluetooth, RFID, Ant+, Zigbee, Z-wave, and UWB. The Bluetooth segment accounts for the largest share of the WPAN market in 2015. The large share of WPAN technologies can be attributed to the fact that these technologies are user friendly, secure, and affordable.

    Browse and in-depth TOC on “Wireless Health Market”
    139 - Tables

    37 - Figures

    214 - Pages

    Allscripts Healthcare Solutions, Inc. (U.S.), AT &T, Inc. (U.S.), Cerner Corporation (U.S.), Omron Corporation (U.S.), Philips Healthcare (U.S.), Verizon Communications, Inc. (U.S.), Qualcomm, Inc. (U.S.), Aerohive Networks, Inc.(U.S.), Vocera Communications, Inc. (U.S.), and Alcatel-Lucent (U.S.) are some of the key players in the wireless health market worldwide.

    About MarketsandMarkets™

    MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

    Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

    MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

    Contact:

    Mr. Shelly Singh
    MarketsandMarkets™ INC.
    630 Dundee Road
    Suite 430
    Northbrook, IL 60062
    USA: 1-888-600-6441
    Email: sales@marketsandmarkets.com
    Visit Our Website: https://www.marketsandmarkets.com


    Mr. Shelly Singh
    1-888-600-6441
    sales@marketsandmarkets.com

    Source: EmailWire.Com

older | 1 | .... | 1105 | 1106 | (Page 1107) | 1108 | 1109 | .... | 1118 | newer